Testicular cancer (TC) is the most common malignancy among men aged 18-39 years ([@pkaa017-B1]), with global incidence rates doubling over the last few decades ([@pkaa017-B2]). Given the introduction of effective chemotherapy in the 1970s ([@pkaa017-B3]), the overall 10-year relative survival rate now approaches 95% ([@pkaa017-B4]). Nonetheless, this success has been accompanied by late life-threatening complications, including second malignant neoplasms (SMN). To date, SMN risk estimates have been largely based on European data, reporting statistically significantly increased 1.5- to 3.5-fold risks ([@pkaa017-B5]) compared with the general population. Estimates have varied widely based on differing calendar years of TC diagnosis, follow-up duration, study design, treatment patterns, and underlying population rates.

To our knowledge, there have been no US-based studies that have comprehensively examined SMN risk after TC in terms of histological type and therapy and focused on recent decades. US-based investigations have been restricted to either seminomatous ([@pkaa017-B9],[@pkaa017-B10]) or nonseminomatous ([@pkaa017-B11],[@pkaa017-B12]) germ cell tumors and largely confined to evaluations of radiotherapy ([@pkaa017-B9],[@pkaa017-B10]). An investigation of nonseminoma TC survivors (TCS) addressed only chemotherapy-associated SMN risks ([@pkaa017-B11]). Two studies \[one restricted to seminoma ([@pkaa017-B9]) and another to nonseminoma ([@pkaa017-B11])\] provided risk estimates for all solid-SMN taken together. Secondary leukemias (n = 15 patients) were evaluated only by Lewinshtein et al. ([@pkaa017-B9]).

To provide new comprehensive information on site-specific relative and absolute risks of second solid-SMN and hematological SMN (heme-SMN) in US TCS treated in the modern era, we studied 24 900 TCS managed initially with surgery only, chemotherapy, or radiotherapy.

Patients and Methods
====================

Patients
--------

We quantified risks of histologically confirmed solid-SMN and heme-SMN, collectively termed SMN, among patients diagnosed with histologically confirmed TC (nonseminoma, seminoma) as a first primary malignancy between January 1, 1973, and December 31, 2014. Patients were reported to 9 population-based registries within the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program ([@pkaa017-B13]). Based on age at TC diagnosis, patients were divided into 4 groups: younger than 30 years, 30--39 years, 40--49 years, and age of 50 years and older. Calendar year of TC diagnosis was divided into 1973--1999 and 2000--2014 in view of the pivotal 1999 study ([@pkaa017-B14]) showing that smaller radiotherapy fields (ie, ipsilateral para-aortic lymph nodes) were as effective as larger fields (ie, ipsilateral iliac and para-aortic lymph nodes) for Stage 1 seminoma. The extent of TC was categorized into localized, regional, and distant disease. Patients were divided into 3 groups based on initial treatment: surgery alone (no or unknown radiotherapy or chemotherapy), chemotherapy only (no or unknown radiotherapy), and radiotherapy only (no or unknown chemotherapy). The SEER program acknowledges underreporting of radiotherapy ([@pkaa017-B15],[@pkaa017-B16]) and chemotherapy ([@pkaa017-B15]). For simplicity, we refer to no or unknown radiotherapy administration as "no radiotherapy" and no or unknown chemotherapy administration as "no chemotherapy." Because few TCS (n = 354) received both radiotherapy and chemotherapy, they were not analyzed separately or included in the three treatment groups but included only in analyses of risks for all 24 900 TCS. Types of surgery included orchiectomy alone or orchiectomy plus resection of regional or distant metastatic sites with lymph node dissection.

Statistical Methods
-------------------

To calculate standardized incidence ratios (SIR), person-years of observation were accrued starting 1 year after TC diagnosis until SMN diagnosis, death, or study end (December 31, 2015), whichever occurred first. To derive SIR, observed numbers of cancers were divided by numbers expected based on age-, sex-, and race-specific cancer incidence rates in the general population, specific for each SEER Program registration area, using previously described methods ([@pkaa017-B17]); 95% confidence intervals (CIs) were derived using SEER Program guidelines ([@pkaa017-B18]). Absolute excess risk (AER) was defined as the absolute excess (observed minus expected) number of SMN per person-years at risk/10 000. SIR and AER calculations were performed using the Multiple-Primary-SIR session of SEER\*Stat ([@pkaa017-B19]). Statistical significance was defined as *P* \< .05 (two-sided). Actuarial cumulative incidence rates of SMN were generated using SAS version 9.4; death and occurrence of other cancers were considered competing events. Gray's test ([@pkaa017-B20]) was used to test the marginal effect (ie, ignoring other predictors) of each potential predictor on SMN incidence. The Fine and Gray competing risk model ([@pkaa017-B21]) was fitted using variables with *P* ≤ .15 by Gray's test. Bonferroni corrections were used for multiple test adjustment for pairwise comparisons between the 3 treatments. Temporal trends in SIR were analyzed for statistical significance using the methods of Breslow ([@pkaa017-B22]).

Results
=======

Study Population
----------------

The study population comprised 24 900 1-year TCS diagnosed at a median age of 33 years (36 for seminoma, 28 for nonseminoma); the interquartile range was 26--40 years. Mean follow-up time was 15 years, with 20 446, 16 169, 8550, and 2952 TCS followed for 5, 10, 20, and 30 years, respectively ([Table 1](#pkaa017-T1){ref-type="table"}). Most (92%) patients were white. TC stage was localized, regional, and distant in 17 274 (69.4%), 4841 (19.4%), and 2412 (9.7%) patients, respectively. Initial management consisted of surgery only (n = 8995), radiotherapy (n = 9058), and chemotherapy (n = 6340), with 2% of patients receiving other treatments (see [Table 1](#pkaa017-T1){ref-type="table"} footnote). During 372 709 person-years of follow-up (mean follow-up = 15 years), 1625 TCS developed a solid-SMN and 228 developed a heme-SMN, including 107 lymphomas, 92 leukemias, and 29 plasma cell dyscrasias.

###### 

Description of US population-based cohort of 24 900 1-year survivors of TC[\*](#tblfn1){ref-type="table-fn"}

  Characteristics                                                                 Patients, No.   Person-years of follow-up[^†^](#tblfn2){ref-type="table-fn"}   Second solid tumors[^‡^](#tblfn3){ref-type="table-fn"}, No.   Second hematologic malignancies[^§^](#tblfn4){ref-type="table-fn"}, No.
  ------------------------------------------------------------------------------- --------------- -------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------
  All patients[^‖^](#tblfn5){ref-type="table-fn"}                                 24 900          372 709                                                        1625                                                          228
   GCT, seminoma                                                                  14 364          210 472                                                        1174                                                          150
   GCT, nonseminoma                                                               10 536          162 237                                                        451                                                           78
  Age at TC diagnosis, y                                                                                                                                                                                                       
   \<30                                                                           9434            154 266                                                        305                                                           65
   30--39                                                                         8803            136 653                                                        539                                                           70
   40--49                                                                         4527            60 326                                                         432                                                           49
   50+                                                                            2136            21 463                                                         349                                                           44
  Calendar year of TC diagnosis                                                                                                                                                                                                
   1973--1999                                                                     13 682          295 356                                                        1433                                                          180
   2000--2014                                                                     11 218          77 353                                                         192                                                           48
  Race                                                                                                                                                                                                                         
   White                                                                          22 916          348 667                                                        1518                                                          210
   African American                                                               564             6819                                                           45                                                            7
   Asian or other                                                                 1209            14 792                                                         62                                                            11
   Unknown                                                                        211             2432                                                           0                                                             0
  Extent of disease                                                                                                                                                                                                            
   Localized                                                                      17 274          258 901                                                        1094                                                          159
   Regional                                                                       4841            76 114                                                         341                                                           43
   Distant                                                                        2412            30 515                                                         149                                                           22
   Unknown                                                                        373             7178                                                           41                                                            4
  Initial treatment for TC[^¶^](#tblfn6){ref-type="table-fn"}                                                                                                                                                                  
   Surgery only                                                                   8995            128 039                                                        372                                                           73
   Radiotherapy, no chemotherapy                                                  9058            156 735                                                        925                                                           108
   Chemotherapy, no radiotherapy                                                  6340            80 700                                                         286                                                           43
   Radiotherapy and chemotherapy                                                  354             4861                                                           28                                                            1
  Initial treatment for seminoma                                                                                                                                                                                               
   Surgery only                                                                   3498            38 441                                                         165                                                           28
   Radiotherapy, no chemotherapy                                                  8865            152 392                                                        901                                                           106
   Chemotherapy, no radiotherapy                                                  1742            16 036                                                         82                                                            14
   Radiotherapy and chemotherapy                                                  174             2410                                                           18                                                            0
  Initial treatment for nonseminoma                                                                                                                                                                                            
   Surgery only                                                                   5497            89 598                                                         207                                                           45
   Radiotherapy, no chemotherapy                                                  193\#           4343                                                           24                                                            2
   Chemotherapy, no radiotherapy                                                  4598            64 664                                                         204                                                           29
   Radiotherapy and chemotherapy                                                  180             2451                                                           10                                                            1
  Patients entering follow-up interval[\*\*](#tblfn8){ref-type="table-fn"}, no.                                                                                                                                                
   1 to \<5 y                                                                     24 900          89 635                                                         173                                                           42
   5 to \<10 y                                                                    20 446          91 420                                                         217                                                           45
   10 to \<20 y                                                                   16 169          122 367                                                        548                                                           68
   20 to \<30 y                                                                   8550            55 610                                                         481                                                           54
   30 to \<35 y                                                                   2952            10 108                                                         140                                                           13
   ≥35 y                                                                          1213            3569                                                           66                                                            6

All patients were diagnosed with TC as a first primary cancer and survived 1 year or more. Mean follow-up was 14.7 years and 15.4 years for men with seminomatous and nonseminomatous GCT, respectively. GCT = germ cell tumor; no chemotherapy = either no chemotherapy was delivered or it is unknown whether chemotherapy was delivered because of known underreporting of chemotherapy to SEER Program registries (see Methods); no radiotherapy = either no radiotherapy was delivered or it is unknown whether radiotherapy was delivered because of known underreporting of radiotherapy to SEER Program registries (see Methods). ICD-O-3 = International Classification of Diseases for Oncology, Third Edition; NOS = not otherwise specified; SEER = National Cancer Institute's Surveillance, Epidemiology, and End Results; TC = testicular cancer.

The total person-years in some groups do not total 372 709 because of rounding. The total person-years for the initial treatment groups of TC totals 370 335, given the exclusion of 533 patients for reasons that are provided in [Table 1](#pkaa017-T1){ref-type="table"}, footnote ¶.

Numbers of solid tumors exclude contralateral TC. Second primary miscellaneous cancers (as defined by the SEER Program; n = 25) are not shown in the table.

Second hematologic malignancies included 107 lymphomas, 92 leukemias, and 29 multiple myelomas or plasmacytomas. Leukemias included acute lymphocytic leukemia (n = 6), acute monocytic leukemia (n = 4), acute myeloid leukemia (n = 40), chronic lymphocytic leukemia (n = 20), chronic myeloid leukemia (n = 14), and other leukemias (n = 8). Lymphomas include non-Hodgkin lymphoma (n = 98, including 30 extranodal) and Hodgkin lymphoma (n = 9).

The seminoma category includes ICD-O-3 histologic codes of 9060/3: dysgerminoma, 9061/3: seminoma, NOS, 9062/3: seminoma, anaplastic, 9063/3: spermatocytic seminoma, 9064/3: germinoma. The nonseminoma category includes ICD-O-3 histologic codes of 9065/3: GCT, nonseminomatous, 9070/3: embryonal carcinoma, NOS, 9071/3: yolk sac tumor, 9072/3: polyembryoma, 9073/3: gonadoblastoma, malignant, 9080/3: teratoma, malignant, NOS, 9081/3: teratocarcinoma, 9082/3: malignant teratoma, undifferentiated, 9083/3: malignant teratoma, intermediate, 9084/3: teratoma with malignant transformation, 9085/3: mixed GCT, 9100/3: choriocarcinoma, NOS, 9101/3: choriocarcinoma combined with other germ cell elements, 9102/3: malignant teratoma, trophoblastic.

A total of 467 patients did not undergo surgery (n = 422) or it is unknown whether surgery was performed (n = 45). Of these 467 patients, 153 were registered as not having received (or unknown if they received) chemotherapy and/or radiotherapy; these 153 patients are not represented in the above treatment subgroups though are included in the total 24 900 patients. Of the remaining 314 patients, those who underwent radiotherapy (n = 58) or chemotherapy (n = 230) are included in the treatment subgroups of the table. A total 354 patients who underwent chemotherapy and radiotherapy (including 26 for whom surgery was not performed) are not included in the treatment subgroups, though they are included in the total of 24 900 patients.

Calendar years of diagnosis for the 193 patients with nonseminoma treated with radiotherapy, no chemotherapy were 1973--1978 (n = 132), 1979--1981 (n = 13), 1982--1999 (n = 30), and 2000--2014 (n = 18).

For patients with seminoma, 14 364, 11 947, 9345, 4677, 1434, and 567 were followed 1, 5, 10, 20, 30, and 35 years and more, respectively. For patients with nonseminoma, 10 536, 8499, 6824, 3873, 1518, and 646 were followed 1, 5, 10, 20, 30, and 35 years or more, respectively.

Solid-SMN
---------

Overall risk of solid-SMN was increased by 1.06-fold (n = 1625, 95% CI = 1.01 to 1.12) ([Table 2](#pkaa017-T2){ref-type="table"}). Statistically significantly increased risks were observed after radiotherapy (n = 925; SIR = 1.13, 95% CI = 1.06 to 1.21) or chemotherapy (n = 286; SIR = 1.26, 95% CI = 1.12 to 1.41) but not after surgery alone (SIR = 0.83, 95% CI = 0.75 to 0.92). After radiotherapy, TCS had 10%-12% excesses of solid-SMN for up to 30 years follow-up, which then increased at 30--34 years (SIR = 1.25, 95% CI = 0.99 to 1.57) and age of 35 years and older (SIR = 1.38, 95% CI = 0.97 to 1.91) after TC diagnosis (*P*~trend~ = .33). Radiotherapy was associated with statistically significantly elevated risks for cancers of stomach (SIR = 1.70), rectum or recto-sigmoid (SIR = 1.44), pancreas (SIR = 2.65), soft tissue (SIR = 2.16), bladder (SIR = 1.54), and thyroid (SIR = 2.01). Statistically significantly increased risks of solid-SMN were apparent 1--5 years after chemotherapy (SIR = 1.74, 95% CI = 1.27 to 2.33), with 20--50% excesses in intervals, beginning 10 years after TC diagnosis, but without discernible temporal trends. Chemotherapy was associated with statistically significantly elevated risks for cancers of pancreas (SIR = 2.17), soft tissue (SIR = 4.01), kidney (SIR = 1.71), and thyroid (SIR = 3.25).

###### 

Risk of second solid and hematologic malignancies according to time since diagnosis of TC and type of initial treatment among 24 900 1-year survivors of TC

                                                                     All patients[^†^](#tblfn10){ref-type="table-fn"}(N = 24 900)   Surgery only (no RT, no chemotherapy)(N = 8995)         Radiotherapy (no chemotherapy)(N = 9058)   Chemotherapy (no radiotherapy)(N = 6340)                                                                                                                                                                                                       
  ------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------------------- ------- ----- ------------------------------------------------------- ------ ----- -------------------------------------------------------- ------
  All nontestis solid tumors                                         1625                                                           1.06 (1.01 to 1.12)[\*](#tblfn9){ref-type="table-fn"}   2.6                                        372                                        0.83 (0.75 to 0.92)                                     −5.9    925   1.13 (1.06 to 1.21)[\*](#tblfn9){ref-type="table-fn"}   6.8    286   1.26 (1.12 to 1.41)[\*](#tblfn9){ref-type="table-fn"}    7.3
  Time since TC diagnosis [^‡^](#tblfn11){ref-type="table-fn"}^,§^                                                                                                                                                                                                                                                                                                                                                                                                                    
   1 to \<5 y                                                        173                                                            1.13 (0.97 to 1.31)                                     2.2                                        41                                         0.86 (0.61 to 1.16)                                     −2.2    85    1.12 (0.89 to 1.38)                                     2.6    45    1.74 (1.27 to 2.33)[\*](#tblfn9){ref-type="table-fn"}    8.9
   5 to \<10 y                                                       217                                                            0.98 (0.85 to 1.12)                                     −0.5                                       47                                         0.76 (0.56 − 1.01)                                      −4      134   1.10 (0.93 to 1.31)                                     3.3    29    0.86 (0.58 to 1.24)                                      −2.3
   10 to \<20 y                                                      548                                                            1.05 (0.96 to 1.14)                                     2.0                                        111                                        0.78 (0.64 to 0.94)                                     −7.5    326   1.11 (0.99 to 1.23)                                     5.8    97    1.27 (1.03 to 1.55)[\*](#tblfn9){ref-type="table-fn"}    8.2
   20 to \<30 y                                                      481                                                            1.06 (0.97 to 1.16)                                     4.8                                        119                                        0.88 (0.73 to 1.05)                                     −8.6    269   1.12 (0.99 to 1.26)                                     12.0   80    1.19 (0.94 to 1.48)                                      11.4
   30 to \<35 y                                                      140                                                            1.13 (0.95 to 1.33)                                     15.7                                       33                                         0.78 (0.54 to 1.10)                                     −23.8   75    1.25 (0.99 to 1.57)                                     37.3   27    1.48 (0.97 to 2.15)                                      45.5
   ≥35 y                                                             66                                                             1.23 (0.95 to 1.57)                                     35.0                                       21                                         1.15 (0.71 to 1.76)                                     21.2    36    1.38 (0.97 to 1.91)                                     63.8   8     1.28 (0.55 to 2.52)                                      32.9
  Age at TC diagnosis[^§^](#tblfn12){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                             
   \<40 y                                                            844                                                            1.17 (1.09 to 1.25)[\*](#tblfn9){ref-type="table-fn"}   4.1                                        197                                        0.82 (0.71 to 0.95)                                     −3.9    427   1.26 (1.14 to 1.39)[\*](#tblfn9){ref-type="table-fn"}   3.9    194   1.50 (1.30 to 1.73)[\*](#tblfn9){ref-type="table-fn"}    9.5
   ≥40 y                                                             781                                                            0.97 (0.90 to 1.04)                                     −3.0                                       175                                        0.84 (0.72 to 0.97)                                     −16.2   498   1.04 (0.95 to 1.13)                                     8.0    92    0.93 (0.75 to 1.15)                                      −5.3
  Extent of disease (TC)[^‖^](#tblfn13){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                          
   Localized                                                         1094                                                           1.00 (0.94 to 1.06)                                     −0.2                                       302                                        0.82 (0.73 to 092                                       −6.3    720   1.09 (1.01 to 1.17)[\*](#tblfn9){ref-type="table-fn"}   4.4    65    1.18 (0.91 to 1.51)                                      4.7
   Regional                                                          341                                                            1.14 (1.03 to 1.27)[\*](#tblfn9){ref-type="table-fn"}   5.7                                        59                                         0.95 (0.73 to 1.23)                                     −1.6    154   1.21 (1.03 to 1.42)[\*](#tblfn9){ref-type="table-fn"}   12.1   117   1.18 (0.97 to 1.41)                                      5.1
   Distant                                                           149                                                            1.45 (1.23 to 1.71)                                     15.3                                       6                                          0.65 (0.24 to 1.41)                                     −15.0   35    2.07 (1.44 to 2.88)[\*](#tblfn9){ref-type="table-fn"}   66.7   97    1.43 (1.16 to 1.75)[\*](#tblfn9){ref-type="table-fn"}    12.4
  Solid cancer site[^¶^](#tblfn14){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                               
   Oral cavity and pharynx                                           58                                                             0.78 (0.59 to 1.01)                                     −0.4                                       10                                         0.45 (0.22 to 0.83)                                     −1.0    26    0.68 (0.44 to 0.99)                                     −0.8   16    1.31 (0.75 to 2.13)                                      0.5
   Esophagus                                                         26                                                             0.98 (0.64 to 1.44)                                     0                                          8                                          1.05 (0.45 to 2.06)                                     0.0     11    0.77 (0.39 to 1.38)                                     −0.2   6     1.54 (0.56 to 3.35)                                      0.3
   Stomach                                                           40                                                             1.35 (0.97 to 1.84)                                     0.3                                        7                                          0.81 (0.33 to 1.68)                                     −0.1    27    1.70 (1.12 to 2.47)[\*](#tblfn9){ref-type="table-fn"}   0.7    5     1.16 (0.38 to 2.71)                                      0.1
   Colon                                                             101                                                            0.96 (0.78 to 1.16)                                     −0.1                                       29                                         0.94 (0.63 to 1.34)                                     −0.2    49    0.86 (0.64 to 1.14)                                     −0.5   20    1.32 (0.81 to 2.04)                                      0.6
   Rectum or recto-sigmoid                                           79                                                             1.30 (1.03 to 1.62)[\*](#tblfn9){ref-type="table-fn"}   0.5                                        19                                         1.06 (0.64 to 1.65)                                     0.1     46    1.44 (1.06 to 1.93)[\*](#tblfn9){ref-type="table-fn"}   0.9    12    1.27 (0.66 to 2.21)                                      0.3
   Liver                                                             26                                                             0.72 (0.47 − 1.06)                                      −0.3                                       4                                          0.38 (0.10 to 0.98)                                     −0.5    15    0.8 (0.45 to 1.32)                                      −0.2   7     1.18 (0.47 to 2.43)                                      0.1
   Pancreas                                                          97                                                             2.35 (1.90 to 2.87)[\*](#tblfn9){ref-type="table-fn"}   1.5                                        21                                         1.75 (1.08 to 2.67)[\*](#tblfn9){ref-type="table-fn"}   0.7     59    2.65 (2.01 to 3.41)[\*](#tblfn9){ref-type="table-fn"}   2.3    13    2.17 (1.16 to 3.71)[\*](#tblfn9){ref-type="table-fn"}    0.9
   Lung and bronchus                                                 189                                                            0.92 (0.80 − 1.06)                                      −0.4                                       30                                         0.52 (0.35 to 0.74)                                     −2.2    123   1.07 (0.89 to 1.27)                                     0.5    33    1.25 (0.86 to 1.75)                                      0.8
   Soft tissue                                                       29                                                             2.13 (1.43 − 3.06)[\*](#tblfn9){ref-type="table-fn"}    0.4                                        3                                          0.69 (0.14 to 2.03)                                     −0.1    14    2.16 (1.18 to 3.62)[\*](#tblfn9){ref-type="table-fn"}   0.5    10    4.01 (1.92 to 7.38)[\*](#tblfn9){ref-type="table-fn"}    0.9
   Melanoma                                                          115                                                            0.94 (0.77 − 1.12)                                      −0.2                                       24                                         0.63 (0.40 to 0.93)                                     −1.1    63    1.04 (0.80 to 1.33)                                     0.2    28    1.3 (0.87 to 1.89)                                       0.8
   Prostate                                                          408                                                            0.87 (0.79 − 0.96)                                      −1.6                                       97                                         0.73 (0.60 to 0.90)                                     −2.7    252   0.97 (0.85 to 1.10)                                     −0.5   53    0.82 (0.62 to 1.08)                                      −1.4
   Bladder                                                           152                                                            1.50 (1.27 − 1.76)[\*](#tblfn9){ref-type="table-fn"}    1.4                                        44                                         1.50 (1.09 to 2.01)[\*](#tblfn9){ref-type="table-fn"}   1.1     86    1.54 (1.23 to 1.90)[\*](#tblfn9){ref-type="table-fn"}   1.9    20    1.47 (0.9 to 2.26)                                       0.8
   Kidney                                                            78                                                             1.1 (0.87 − 1.37)                                       0.2                                        27                                         1.27 (0.84 to 1.84)                                     0.5     27    0.74 (0.49 to 1.08)                                     −0.6   20    1.71 (1.04 to 2.64)[\*](#tblfn9){ref-type="table-fn"}    1.0
   Brain and nervous system                                          31                                                             0.95 (0.64 − 1.35)                                      0                                          6                                          0.58 (0.21 to 1.26)                                     −0.3    18    1.15 (0.68 to 1.81)                                     0.2    5     0.84 (0.27 to 1.97)                                      −0.1
   Thyroid                                                           60                                                             1.95 (1.49 to 2.52)[\*](#tblfn9){ref-type="table-fn"}   0.8                                        11                                         1.09 (0.55 to 1.96)                                     0.1     28    2.01 (1.34 to 2.91)[\*](#tblfn9){ref-type="table-fn"}   0.9    20    3.25 (1.99 to 5.02)[\*](#tblfn9){ref-type="table-fn"}    1.7
   Kaposi sarcoma                                                    11                                                             0.64 (0.32 to 1.15)                                     −0.2                                       5                                          0.85 (0.28 to 1.98)                                     −0.1    3     0.41 (0.08 to 1.19)                                     −0.3   3     0.84 (0.17 to 2.45)                                      −0.1
  All hematologic malignancies                                       228                                                            1.25 (1.10 to 1.43)[\*](#tblfn9){ref-type="table-fn"}   1.2                                        73                                         1.30 (1.02 to 1.64)[\*](#tblfn9){ref-type="table-fn"}   1.3     108   1.18 (0.97 to 1.42)                                     1.0    43    1.42 (1.03 to 1.94)[\*](#tblfn9){ref-type="table-fn"}    1.6
   All lymphomas\#                                                   107                                                            1.02 (0.84 to 1.23)                                     0.1                                        38                                         1.16 (0.82 to 1.59)                                     0.4     52    1.01 (0.75 to 1.32)                                     0.0    14    0.76 (0.42 to 1.28)                                      −0.5
   Plasma cell dyscrasias                                            29                                                             1.27 (0.85 to 1.83)                                     0.2                                        6                                          0.90 (0.33 to 1.95)                                     −0.1    17    1.39 (0.81 to 2.23)                                     0.3    6     1.77 (0.65 to 3.86)                                      0.3
   All leukemias[\*\*](#tblfn16){ref-type="table-fn"}                92                                                             1.69 (1.37 to 2.08)[\*](#tblfn9){ref-type="table-fn"}   1.0                                        29                                         1.76 (1.18 to 2.52)[\*](#tblfn9){ref-type="table-fn"}   1.0     39    1.39 (0.99 to 1.91)                                     0.7    23    2.68 (1.70 to 4.01)[\*](#tblfn9){ref-type="table-fn"}    1.8
  Time since TC diagnosis                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   1 to \<5 y                                                        26                                                             3.96 (2.59 to 5.80)[\*](#tblfn9){ref-type="table-fn"}   2.2                                        10                                         4.57 (2.19 to 8.40)[\*](#tblfn9){ref-type="table-fn"}   2.5     7     2.34 (0.94 to 4.82)                                     1.2    9     7.18 (3.28 to 13.62)[\*](#tblfn9){ref-type="table-fn"}   3.6
   5 to \<10 y                                                       20                                                             2.33 (1.42 to 3.60)[\*](#tblfn9){ref-type="table-fn"}   1.3                                        5                                          1.96 (0.64 to 4.58)                                     0.8     9     2.03 (0.93 to 3.86)                                     1.2    6     4.16 (1.53 to 9.05)[\*](#tblfn9){ref-type="table-fn"}    2.3
   10 to \<20 y                                                      22                                                             1.22 (0.76 to 1.84)                                     0.3                                        5                                          0.97 (0.31 to 2.26)                                     0.0     11    1.13 (0.56 to 2.02)                                     0.2    5     1.77 (0.58 to 4.14)                                      0.9
   20 to \<30 y                                                      19                                                             1.28 (0.77 to 1.99)                                     0.7                                        8                                          1.77 (0.76 to 3.48)                                     1.8     9     1.16 (0.53 to 2.20)                                     0.5    2     0.89 (0.11 to 3.22)                                      −0.2
   30 to \<35                                                        3                                                              0.71 (0.15 to 2.07)                                     −1.2                                       0                                          0 (0 to 2.58)                                           −3.8    2     0.97 (0.12 to 3.52)                                     −0.1   1     1.62 (0.04 to 9.05)                                      2.0
   ≥35 y                                                             2                                                              1.02 (0.12 to 3.69)                                     0.1                                        1                                          1.51 (0.04 to 8.42)                                     2.6     1     1.03 (0.03 to 5.74)                                     0.2    0     0 (0 to 16.76)                                           −4.1
  Specific leukemias[^††^](#tblfn17){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                             
   AML                                                               44                                                             2.98 (2.17 to 4.00)[\*](#tblfn9){ref-type="table-fn"}   0.8                                        14                                         3.09 (1.69 to 5.19)[\*](#tblfn9){ref-type="table-fn"}   0.7     13    1.73 (0.92 to 2.95)                                     0.4    17    7.13 (4.15 to 11.41)[\*](#tblfn9){ref-type="table-fn"}   1.8
   CLL                                                               20                                                             0.89 (0.54 to 1.37)                                     −0.1                                       7                                          1.06 (0.43 to 2.19)                                     0.0     12    0.99 (0.51 to 1.72)                                     0.0    0     0 (0 to 1.14)                                            −0.4
   CML                                                               14                                                             1.76 (0.96 to 2.96)                                     0.2                                        5                                          2.00 (0.65 to 4.68)                                     0.2     7     1.80 (0.72 to 3.70)                                     0.2    2     1.46 (0.18 to 5.27)                                      0.1

Statistically significant elevated SIR. AER = absolute excess risk (observed -- expected) \* person-years at risk/10 000; AML = acute myeloid leukemia; CI = confidence interval; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; RT = radiotherapy; SIR = standardized incidence ratio; SMN = second-malignant neoplasms; TC = testicular cancer; TCS = testicular cancer survivors.

A total of 467 patients did not undergo surgery (n = 422) or it is unknown whether surgery was performed (n = 45). Of these 467 patients, a total of 153 were registered as not having received (or unknown if they received) chemotherapy and/or radiotherapy; these 153 patients are not represented in the above treatment subgroups though are included in the "all patients" analysis for the total 24 900 patients. Of the remaining 314 patients, those who underwent radiotherapy (n = 58) or chemotherapy (n = 230) are included in the treatment subgroups of the table. A total of 354 patients who underwent chemotherapy and radiotherapy (including 26 for whom surgery was not performed) are not included in the treatment subgroups though are included in the analysis of all 24 900 TCS.

Among TCS diagnosed between 2000 and 2014 for whom latencies beyond 15 years were not yet attainable, for the 192 second solid nontestis cancers that developed, the 1- to \<5-, 5- to 10-, and 10- to 15-year SIRs were 1.11 (95% CI = 0.88 to 1.39), 0.84 (95% CI = 0.64 to 1.08), and 1.26 (95% CI = 0.95 to 1.65), respectively; these values were similar to the 1- to \<5-, 5- to 10-, and 10- to 20-year data from TCS diagnosed between 1973 and 1999 in whom 1433 second solid nontestis cancers have developed, with SIRs of 1.14 (95% CI = 0.93 to 1.39), 1.05 (95% CI = 0.89 to 1.23), and 1.03 (95% CI = 0.94 to 1.12), respectively.

Risks of solid, nontestis cancers were statistically significantly increased among those aged younger than 30 years (SIR = 1.29, 95% CI = 1.15 to 1.44; AER = 4.4) and 30--39 years (SIR = 1.11, 95% CI = 1.01 to 1.20; AER = 3.8) at time of TC diagnosis but not for those aged 40--49 years (SIR = 0.96, 95% CI = 0.87 to 1.05; AER = −3.0) and 50 years and older (SIR = 0.98, 95% CI = 0.88 to 1.09; AER = −3.0).

Patients with unknown TC stage (see [Table 1](#pkaa017-T1){ref-type="table"}) are not shown.

Solid-SMN not shown in the table include (as classified by the SEER program) mesothelioma (n = 7) and cancers of the anus and anal canal (n = 5), bones and joints (n = 2), eye and orbit (n = 3), gallbladder (n = 3), intrahepatic bile duct (n = 5), larynx (n = 25), male breast (n = 2), nose, nasal cavity and middle ear (n = 4), biliary tract (n = 11), other digestive organs (n = 4), other endocrine sites (n = 1), other nonepithelial skin (n = 13), other urinary organs (n = 1), penis and other male genitalia sites (n = 3), renal pelvis (n = 7), retroperitoneum (n = 4), small intestines (n = 14), thymus (n = 2), and ureter (n = 9), with "other" referring to sites not categorized by SEER as described at: <https://training.seer.cancer.gov/modules_site_spec.html>.

Among patients treated for seminoma, 75 developed lymphoma (SIR = 1.10, 95% CI = 0.87 to 1.38), and among patients treated for nonseminoma, 32 developed lymphoma (SIR = 0.87, 95% CI = 0.59 to 1.23). For both seminoma and nonseminoma histologies, SIRs were not statistically significantly elevated or decreased within any treatment subgroup (surgery alone, chemotherapy, or radiotherapy) or within any specific time frame (1--5, 5--10, 10--20, 20--30, 30--35 and ≥35 y) after TC diagnosis.

Second leukemias include acute lymphocytic leukemia (n = 6), acute monocytic (n = 4) and myeloid (n = 40) leukemias (n = 44), CLL (n = 20), CML (n = 14), and other leukemias (n = 8). Risks of leukemias were statistically significantly increased among those aged \<30 years (SIR = 3.14, 95% CI = 2.16 to 4.40; AER = 1.5) and 50 years and older (SIR = 1.72, 95% CI = 1.05 to 2.65; AER = 3.9) at the time of TC diagnosis but not the age groups of 30--39 years (SIR = 1.37, 95% CI = 0.88 to 2.04) or 40--49 years (SIR = 1.02, 95% CI = 0.57 to 1.69).

Results are shown for the 3 most common leukemias occurring after TC. For acute lymphocytic leukemia (n = 6), the SIR was 1.90 (95% CI = 0.70 to 4.14) and for acute monocytic leukemia (n = 4) the SIR was 4.58 (95% CI = 1.25 to 11.7).

‡‡No radiotherapy" implies either no radiotherapy was administered or it is unknown whether radiotherapy was delivered; likewise "No chemotherapy" implies either no chemotherapy or it is unknown whether chemotherapy was delivered (please refer to Methods).

Hematologic SMN
---------------

Overall risk of heme-SMN was statistically significantly increased 1.25-fold (n = 228; 95% CI = 1.10-fold to 1.43-fold) ([Table 2](#pkaa017-T2){ref-type="table"}). Risks for lymphoma (SIR = 1.02) and plasma cell dyscrasias (SIR = 1.27) were not statistically significantly increased overall or after any treatment modality. In contrast, a statistically significantly increased 1.7-fold (95% CI = 1.37-fold to 2.08-fold) leukemia risk occurred among all TCS, with the most common type being acute myeloid leukemia (AML; n = 44), followed by chronic lymphocytic leukemia (CLL; n = 20) and chronic myeloid leukemia (CML; n = 14). An overall statistically significantly increased 2.68-fold (95% CI = 1.70-fold to 4.01-fold) risk of leukemia occurred after chemotherapy, with excesses restricted to 1--5 years (SIR = 7.18, 95% CI = 3.28 to 13.62) and 5--10 years (SIR = 4.16, 95% CI = 1.53 to 9.05) after TC diagnosis. Surgery alone was associated with increased leukemia risks (SIR = 1.76, 95% CI = 1.18 to 2.52), confined to 1-5 years (SIR = 4.57, 95% CI = 2.19 to 8.40) after TC diagnosis. Radiotherapy was associated with nonstatistically significant 2- to 2.3-fold excess leukemias during the first decade after TC diagnosis but decreased to expectation thereafter. Among the most common secondary leukemias (AML, CLL, and CML), only AML was associated with statistically significantly elevated risks (SIR = 7.13, 95% CI = 4.15 to 11.41) after chemotherapy, with statistically significant excesses (SIR = 3.09, 95% CI = 1.69 to 5.19) also following surgery alone.

Solid-SMN After Seminoma and Nonseminoma
----------------------------------------

***Seminoma*.** Among patients with seminoma, statistically significant overall excesses of solid-SMN followed either radiotherapy (SIR = 1.13, 95% CI = 1.06 to 1.21) or chemotherapy (SIR = 1.28, 95% CI = 1.02 to 1.58), but not surgery alone (SIR = 0.87, 95% CI = 0.74 to 1.01) ([Table 3](#pkaa017-T3){ref-type="table"}). After radiotherapy, statistically nonsignificant 1.11- to 1.12-fold risks of solid-SMN occurred during the first 30 years of follow-up, with statistically significant excesses thereafter (SIR = 1.28, 95% CI 1.04 to 1.55; *P*~trend~ = .07). Radiotherapy was associated with statistically significantly elevated risks of pancreatic cancer in 10- to 20-year (SIR = 2.61), 20- to 30-year (SIR = 2.88), and 30 or greater-year (SIR = 4.83) intervals (*P*~trend~ = .006), whereas statistically significant bladder cancer excesses occurred at 1--10 years (SIR = 1.69) and 30+ years (SIR = 2.00). Excesses of soft tissue cancer were restricted to the 1- to 10-year interval (SIR = 2.88, 95% CI = 1.06 to 6.26), with nonstatistically significant 2-fold risks for 10--30 years (median latency = 11.7 years; range = 5.2--28.3 years). After chemotherapy for seminoma, statistically significantly increased excesses were observed for AML (n = 6, SIR = 10.2, 95% CI = 3.75 to 22.2; data not shown in [Table 3](#pkaa017-T3){ref-type="table"}), but not for any site-specific solid-SMN.

###### 

Site-specific risks of selected second solid cancers after TC according to time since diagnosis of TC, histologic type, and type of initial treatment among 24 900 1-year survivors of TC

  Second cancer site[^†^](#tblfn20){ref-type="table-fn"} and type of initial treatment for TC   1 to \<10 y   10 to \<20 y                                             20 to \<30 y                                             ≥30 y                                                    Total                                                                                                                                                                                                                                                                           
  --------------------------------------------------------------------------------------------- ------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------- -------------------------------------------------------- --------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Seminoma: time since diagnosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   All solid (nontestis) cancer sites                                                           SURG          47                                                       0.76 (0.56 to 1.01)                                      52                                                       0.82 (0.61 to 1.07)   47                                                       1.00 (0.73 to 1.33)   19                                                       1.12 (0.67 to 1.75)                                      165                                                      0.87 (0.74 to 1.01)
  RT                                                                                            218           1.12 (0.97 to 1.28)                                      321                                                      1.11 (0.99 to 1.24)                                      262                   1.12 (0.99 to 1.27)                                      100                   1.28 (1.04 to 1.55)[\*](#tblfn19){ref-type="table-fn"}   901                                                      1.13 (1.06 to 1.21)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         36            1.35 (0.95 to 1.87)                                      25                                                       1.04 (0.67 to 1.53)                                      16                    1.38 (0.79 to 2.24)                                      5                     2.67 (0.87 to 6.23)                                      82                                                       1.28 (1.02 to 1.58)[\*](#tblfn19){ref-type="table-fn"}   
   Thyroid cancer                                                                               SURG          3                                                        1.96 (0.40 to 5.72)                                      3                                                        2.69 (0.56 to 7.87)   0                                                        0 (0 to 6.03)         0                                                        0 (0 to 19.8)                                            6                                                        1.74 (0.64 to 3.79)
  RT                                                                                            11            2.38 (1.19 to 4.26)[\*](#tblfn19){ref-type="table-fn"}   10                                                       1.98 (0.95 to 3.64)                                      4                     1.31 (0.36 to 3.36)                                      1                     1.15 (0.03 to 6.41)                                      26                                                       1.91 (1.25 to 2.80)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         3             3.77 (0.78 to 11.0)                                      0                                                        0 (0 to 7.51)                                            0                     0 (0 to 20.0)                                            0                     0 (0 to 164.5)                                           3                                                        2.01 (0.41 to 5.87)                                      
   Gastric cancer                                                                               SURG          1                                                        0.75 (0.02 to 4.17)                                      1                                                        0.81 (0.02 to 4.53)   1                                                        1.18 (0.03 to 6.60)   1                                                        3.22 (0.08 to 17.8)                                      4                                                        1.08 (0.29 to 2.75)
  RT                                                                                            3             0.71 (0.15 to 2.07)                                      10                                                       1.79 (0.86 to 3.29)                                      9                     2.16 (0.99 to 4.09)                                      4                     2.80 (0.76 to 7.18)                                      26                                                       1.69 (1.11 to 2.47)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         1             1.85 (0.05 to 10.3)                                      0                                                        0 (0 to 8.22)                                            0                     0 (0 to 18.1)                                            0                     0 (0 to 102.6)                                           1                                                        0.81 (0.02 to 4.54)                                      
   Pancreatic cancer                                                                            SURG          6                                                        3.65 (1.34 to 7.94)[\*](#tblfn19){ref-type="table-fn"}   1                                                        0.59 (0.01 to 3.28)   2                                                        1.51 (0.18 to 5.45)   3                                                        5.48 (1.13 to 16.0)[\*](#tblfn19){ref-type="table-fn"}   12                                                       2.30 (1.19 to 4.02)[\*](#tblfn19){ref-type="table-fn"}
  RT                                                                                            6             1.21 (0.44 to 2.63)                                      20                                                       2.61 (1.60 to 4.04)[\*](#tblfn19){ref-type="table-fn"}   19                    2.88 (1.74 to 4.50)[\*](#tblfn19){ref-type="table-fn"}   12                    4.83 (2.50 to 8.44)[\*](#tblfn19){ref-type="table-fn"}   57                                                       2.63 (1.99 to 3.41)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         1             1.44 (0.04 to 8.01)                                      0                                                        0 (0 to 5.55)                                            1                     2.99 (0.08 to 16.7)                                      0                     0 (0 to 60.7)                                            2                                                        1.14 (0.14 to 4.12)                                      
   Rectum or recto-sigmoid cancer                                                               SURG          2                                                        0.74 (0.09 to 2.69)                                      3                                                        1.16 (0.24 to 3.40)   3                                                        1.82 (0.38 to 5.33)   0                                                        0 (0 to 7.72)                                            8                                                        1.08 (0.47 to 2.13)
  RT                                                                                            13            1.49 (0.79-2.55)                                         16                                                       1.34 (0.77 to 2.18)                                      14                    1.73 (0.95 to 2.91)                                      2                     0.90 (0.11 to 3.27)                                      45                                                       1.45 (1.06 to 1.94)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         2             1.67 (0.20 to 6.04)                                      2                                                        2.02 (0.25 to 7.31)                                      1                     2.43 (0.06 to 13.6)                                      0                     0 (0 to 67.0)                                            5                                                        1.89 (0.61 to 4.40)                                      
   Bladder cancer                                                                               SURG          6                                                        1.46 (0.54 to 3.18)                                      8                                                        1.86 (0.80 to 3.66)   7                                                        2.05 (0.82 to 4.22)   1                                                        0.68 (0.02 to 3.77)                                      22                                                       1.65 (1.04 to 2.50)[\*](#tblfn19){ref-type="table-fn"}
  RT                                                                                            21            1.69 (1.04 to 2.58)[\*](#tblfn19){ref-type="table-fn"}   24                                                       1.28 (0.82 to 1.90)                                      25                    1.51 (0.98 to 2.23)                                      13                    2.00 (1.07 to 3.43)[\*](#tblfn19){ref-type="table-fn"}   83                                                       1.53 (1.22 to 1.89)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         1             0.65 (0.02 to 3.60)                                      5                                                        3.35 (1.09 to 7.81)[\*](#tblfn19){ref-type="table-fn"}   0                     0 (0 to 4.84)                                            1                     6.52 (0.17 to 36.4)                                      7                                                        1.77 (0.71 to 3.65)                                      
   Kidney cancer                                                                                SURG          3                                                        1.04 (0.21 to 3.03)                                      1                                                        0.35 (0.01 to 1.94)   1                                                        0.50 (0.01 to 2.80)   1                                                        1.41 (0.04 to 7.86)                                      6                                                        0.71 (0.26 to 1.54)
  RT                                                                                            7             0.78 (0.32 to 1.62)                                      7                                                        0.53 (0.21 to 1.10)                                      10                    1.00 (0.48 to 1.84)                                      2                     0.61 (0.07 to 2.19)                                      26                                                       0.73 (0.48 to 1.08)                                      
  CHEMO                                                                                         0             0 (0 to 2.57)                                            0                                                        0 (0 to 3.06)                                            2                     3.67 (0.44 to 13.3)                                      0                     0 (0 to 45.6)                                            2                                                        0.61 (0.07 to 2.21)                                      
   Soft tissue cancer                                                                           SURG          0                                                        0 (0 to 5.60)                                            1                                                        2.00 (0.05 to 11.1)   0                                                        0 (0 to 12.1)         0                                                        0 (0 to 33.7)                                            1                                                        0.64 (0.02 to 3.54)
  RT                                                                                            6             2.88 (1.06 to 6.26)[\*](#tblfn19){ref-type="table-fn"}   5                                                        2.22 (0.72 to 5.18)                                      3                     2.01 (0.42 to 5.88)                                      0                     0 (0 to 7.56)                                            14                                                       2.22 (1.21 to 3.72)[\*](#tblfn19){ref-type="table-fn"}   
  CHEMO                                                                                         1             3.2 (0.08 to 17.8)                                       0                                                        0 (0 to 18.4)                                            1                     12.8 (0.32 to 71.1)                                      0                     0 (0 to 300.0)                                           2                                                        3.31 (0.40 to 12.0)                                      
  Nonseminoma: time since diagnosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   All solid (nontestis) cancer sites                                                           SURG          41                                                       0.86 (0.62 to 1.16)                                      59                                                       0.76 (0.58 to 0.97)   72                                                       0.81 (0.63 to 1.02)   35                                                       0.81 (0.56 to 1.12)                                      207                                                      0.80 (0.70 to 0.92)
  RT                                                                                            1             0.43 (0.01 to 2.41)                                      5                                                        0.97 (0.31 to 2.26)                                      7                     0.91 (0.37 to 1.87)                                      11                    1.44 (0.72 to 2.58)                                      24                                                       1.05 (0.67 to 1.56)                                      
  CHEMO                                                                                         38            1.15 (0.82 to 1.58)                                      72                                                       1.38 (1.08 to 1.74)[\*](#tblfn19){ref-type="table-fn"}   64                    1.15 (0.89 to 1.47)                                      30                    1.32 (0.89 to 1.89)                                      204                                                      1.25 (1.08 to 1.43)[\*](#tblfn19){ref-type="table-fn"}   
   Thyroid cancer                                                                               SURG          0                                                        0 (0 to 1.87)                                            2                                                        0.89 (0.11 to 3.21)   2                                                        1.15 (0.14 to 4.14)   1                                                        1.56 (0.04 to 8.72)                                      5                                                        0.76 (0.25 to 1.77)
  RT                                                                                            0             0 (0 to 63.4)                                            1                                                        12.9 (0.33 to 71.7)                                      0                     0 (0 to 74.3)                                            1                     10.8 (0.27 to 60.0)                                      2                                                        6.33 (0.77 to 22.9)                                      
  CHEMO                                                                                         8             5.29 (2.28 to 10.4)[\*](#tblfn19){ref-type="table-fn"}   4                                                        2.48 (0.68 to 6.35)                                      1                     0.85 (0.02 to 4.75)                                      4                     11.0 (3.00 to 28.2)[\*](#tblfn19){ref-type="table-fn"}   17                                                       3.65 (2.13 to 5.84)[\*](#tblfn19){ref-type="table-fn"}   
   Gastric cancer                                                                               SURG          0                                                        0 (0 to 3.74)                                            1                                                        0.65 (0.02 to 3.62)   2                                                        1.25 (0.15 to 4.53)   0                                                        0 (0 to 4.90)                                            3                                                        0.62 (0.13 to 1.80)
  RT                                                                                            0             0 (0 to 57.7)                                            0                                                        0 (0 to 30.5)                                            0                     0 (0 to 24.1)                                            1                     7.4 (0.19 to 41.2)                                       1                                                        2.11 (0.05 to 11.8)                                      
  CHEMO                                                                                         0             0 (0 to 5.56)                                            2                                                        1.97 (0.24 to 7.10)                                      1                     1.00 (0.03 to 5.59)                                      1                     2.55 (0.06 to 14.2)                                      4                                                        1.30 (0.36 to 3.34)                                      
   Pancreatic cancer                                                                            SURG          1                                                        0.94 (0.02 to 5.22)                                      3                                                        1.52 (0.31 to 4.44)   5                                                        2.05 (0.67 to 4.79)   0                                                        0 (0 to 2.81)                                            9                                                        1.32 (0.61 to 2.52)
  RT                                                                                            0             0 (0 to 60.0)                                            0                                                        0 (0 to 28.8)                                            0                     0 (0 to 18.8)                                            2                     8.71 (1.06 to 31.5)[\*](#tblfn19){ref-type="table-fn"}   2                                                        3.25 (0.39 to 11.7)                                      
  CHEMO                                                                                         0             0 (0 to 5.10)                                            5                                                        3.81 (1.24 to 8.90)[\*](#tblfn19){ref-type="table-fn"}   5                     3.29 (1.07 to 7.69)[\*](#tblfn19){ref-type="table-fn"}   1                     1.46 (0.04 to 8.15)                                      11                                                       2.60 (1.30 to 4.65)[\*](#tblfn19){ref-type="table-fn"}   
   Rectum or recto-sigmoid cancer                                                               SURG          2                                                        0.96 (0.12 to 3.46)                                      5                                                        1.43 (0.46 to 3.34)   3                                                        0.83 (0.17 to 2.44)   1                                                        0.72 (0.02 to 4.00)                                      11                                                       1.04 (0.52 to 1.86)
  RT                                                                                            0             0 (0 to 32.8)                                            0                                                        0 (0 to 16.2)                                            0                     0 (0 to 12.2)                                            1                     4.31 (0.11 to 24.0)                                      1                                                        1.14 (0.03 to 6.36)                                      
  CHEMO                                                                                         1             0.69 (0.02 to 3.87)                                      2                                                        0.85 (0.10 to 3.09)                                      3                     1.32 (0.27 to 3.85)                                      1                     1.32 (0.03 to 7.35)                                      7                                                        1.03 (0.41 to 2.12)                                      
   Bladder cancer                                                                               SURG          3                                                        1.12 (0.23 to 3.26)                                      7                                                        1.49 (0.60 to 3.07)   7                                                        1.25 (0.50 to 2.57)   5                                                        1.60 (0.52 to 3.74)                                      22                                                       1.36 (0.86 to 2.07)
  RT                                                                                            0             0 (0 to 22.8)                                            0                                                        0 (0 to 10.4)                                            2                     3.76 (0.46 to 13.6)                                      1                     1.69 (0.04 to 9.43)                                      3                                                        1.83 (0.38 to 5.35)                                      
  CHEMO                                                                                         0             0 (0 to 2.12)                                            9                                                        3.03 (1.38 to 5.74)[\*](#tblfn19){ref-type="table-fn"}   3                     0.88 (0.18 to 2.58)                                      1                     0.63 (0.02 to 3.54)                                      13                                                       1.34 (0.71 to 2.30)                                      
   Kidney cancer                                                                                SURG          6                                                        2.57 (0.94 to 5.59)                                      5                                                        1.22 (0.40 to 2.85)   6                                                        1.36 (0.50 to 2.97)   4                                                        2.00 (0.55 to 5.13)                                      21                                                       1.64 (1.01 to 2.50)[\*](#tblfn19){ref-type="table-fn"}
  RT                                                                                            0             0 (0 to 40.2)                                            0                                                        0 (0 to 18.4)                                            1                     3.42 (0.09 to 19.0)                                      0                     0 (0 to 11.3)                                            1                                                        1.10 (0.03 to 6.12)                                      
  CHEMO                                                                                         4             2.35 (0.64 to 6.02)                                      7                                                        2.49 (1.00 to 5.12)                                      5                     1.76 (0.57 to 4.10)                                      2                     1.86 (0.22 to 6.71)                                      18                                                       2.13 (1.26 to 3.37)[\*](#tblfn19){ref-type="table-fn"}   
   Soft tissue cancer                                                                           SURG          1                                                        1.16 (0.03 to 6.48)                                      1                                                        1.11 (0.03 to 6.18)   0                                                        0 (0 to 5.24)         0                                                        0 (0 to 12.8)                                            2                                                        0.73 (0.09 to 2.62)
  RT                                                                                            0             0 (0 to 121.2)                                           0                                                        0 (0 to 88.7)                                            0                     0 (0 to 74.3)                                            0                     0 (0 to 77.4)                                            0                                                        0 (0 to 21.8)                                            
  CHEMO                                                                                         3             4.63 (0.96 to 13.5)                                      2                                                        3.17 (0.38 to 11.5)                                      2                     4.39 (0.53 to 15.9)                                      1                     6.46 (0.16 to 36.0)                                      8                                                        4.24 (1.83 to 8.35)[\*](#tblfn19){ref-type="table-fn"}   

Statistically significantly elevated SIR. CHEMO = administration of chemotherapy without (or unknown) radiotherapy administration; CI = confidence interval; RT = administration of radiotherapy without (or unknown) chemotherapy administration; SIR = standardized incidence ratio; SURG = surgery without (or unknown) administration of radiotherapy or chemotherapy; TC = testicular cancer.

Solid cancers listed in this table are restricted to those for which statistically significantly increased risks were observed in [Table 2](#pkaa017-T2){ref-type="table"}.

***Nonseminoma*.** Among patients with nonseminoma, chemotherapy was associated with overall excesses of solid-SMN (SIR = 1.25, 95% CI = 1.08 to 1.43), with statistically significantly increased risks for cancers of thyroid (SIR = 3.65), pancreas (SIR = 2.60), kidney (SIR = 2.13), and soft tissue (SIR = 4.24) ([Table 3](#pkaa017-T3){ref-type="table"}) and AML (n = 9, SIR = 5.44, 95% CI = 2.49 to 10.3; data not shown in [Table 3](#pkaa017-T3){ref-type="table"}). Given the relatively small numbers of cancers at each site (n = 8--18), strong discernible temporal trends were not apparent. No overall increased solid-SMN risk was observed after surgery alone (SIR = 0.80) or radiotherapy (SIR = 1.05), but few patients received radiotherapy (n = 193). Site-specific excesses of solid-SMN after surgery alone were confined to kidney cancer (SIR = 1.64), with no apparent temporal trend.

Cumulative Incidence of Solid-SMN
---------------------------------

[Figure 1](#pkaa017-F1){ref-type="fig"} shows the cumulative incidence of solid-SMN (accounting for competing risks of death or other cancers) among TCS by treatment group. Following surgery alone, chemotherapy, and radiotherapy, 15-year cumulative incidences of solid-SMN were 2.2% (95% CI = 1.9% to 2.6%), 2.8% (95% CI = 2.3% to 3.3%), and 4.9% (95% CI = 4.4% to 5.4%), whereas 30-year cumulative incidences were 8.8% (95% CI = 7.8% to 9.9%), 10.1% (95% CI = 8.8% to 11.5%), and 16.9% (95% CI = 15.7% to 18.1%), respectively. Differences between each treatment group were statistically significant: radiotherapy vs surgery alone (*P* \< .001), chemotherapy vs surgery alone (*P* = .050), and radiotherapy vs chemotherapy (*P* \< .001). Among TCS diagnosed from 1973 to 1999 vs 2000 to 2014 and treated with radiotherapy, 15-year cumulative incidences of solid-SMN did not differ statistically significantly (*P* = .41): 4.8% (95% CI = 4.3% to 5.3%) and 5.2% (95% CI = 4.1% to 6.5%), respectively. [Table 4](#pkaa017-T4){ref-type="table"} shows the Fine and Gray competing risk model of solid-SMN cumulative incidence with statistically significant variables, including age of 40 years and older (hazard ratio \[HR\] = 2.96, 95% CI = 2.67 to 3.28), seminoma histology (HR = 1.42, 95% CI = 1.21 to 1.66), and chemotherapy or radiotherapy (HR = 1.26, 95% CI = 1.08 to 1.47 and HR = 1.35, 95% CI = 1.17 to 1.57, respectively) vs surgery alone. [Figure 2](#pkaa017-F2){ref-type="fig"} shows the cumulative incidence of leukemias (accounting for competing risks of death or other cancers) by treatment group. Following surgery alone, chemotherapy, and radiotherapy, 15-year cumulative incidences were 0.2% (95% CI = 0.1% to 0.3%), 0.4% (95% CI = 0.3% to 0.7%), and 0.3% (95% CI = 0.2% to 0.5%), respectively, and 30-year cumulative incidences were 0.7% (95% CI = 0.4% to 1.0%), 0.6% (95% CI = 0.3% to 0.9%), and 0.6% (95% CI = 0.4% to 0.9%), respectively.

![Cumulative incidence of nontestis solid malignant neoplasms after initial testicular cancer (TC) diagnosis, accounting for competing risks of death or development of another cancer after initial TC diagnosis (see Methods), grouped by initial treatment. The 95% confidence intervals are shown as shaded regions. The cumulative incidence functions were statistically different between the 3 treatment curves (*P* \< .001). Pairwise comparisons (with Bonferroni correction applied to control for type I error) surgery alone vs radiotherapy (*P* \< .001), surgery alone vs chemotherapy (*P* = .05), and chemotherapy vs radiotherapy (*P* \< .001) were statistically significant. Chemo = chemotherapy; RT = radiotherapy.](pkaa017f1){#pkaa017-F1}

![Cumulative incidence of leukemias after initial testicular cancer (TC) diagnosis, accounting for competing risks of death or development of another cancer after initial TC diagnosis (see Methods), grouped by initial treatment. The 95% confidence intervals are shown as shaded regions. The cumulative incidence functions were similar between the three treatment curves (*P* = .84). Chemo = chemotherapy; RT = radiotherapy.](pkaa017f2){#pkaa017-F2}

###### 

Multivariable competing-risk model of potential risk factors affecting the cumulative incidence of second primary solid cancers in TCS

  Variables                                                               HR (95% CI)                                              *P* ~adjusted~
  ----------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------
  Age, ≥40[\*](#tblfn21){ref-type="table-fn"} vs \<40 y                   2.96 (2.67 to 3.28)[\*](#tblfn21){ref-type="table-fn"}   \<.001[\*](#tblfn21){ref-type="table-fn"}
  Race, other race[\*](#tblfn21){ref-type="table-fn"} vs white            1.17 (0.95 to 1.43)                                      .14
  Histology, seminoma[\*](#tblfn21){ref-type="table-fn"} vs nonseminoma   1.42 (1.21 to 1.66)[\*](#tblfn21){ref-type="table-fn"}   \<.001[\*](#tblfn21){ref-type="table-fn"}
  Chemotherapy[\*](#tblfn21){ref-type="table-fn"} vs surgery alone        1.26 (1.08 to 1.47)[\*](#tblfn21){ref-type="table-fn"}   .01[\*](#tblfn21){ref-type="table-fn"}
  Radiotherapy[\*](#tblfn21){ref-type="table-fn"} vs surgery alone        1.35 (1.17 to 1.57)[\*](#tblfn21){ref-type="table-fn"}   .001[\*](#tblfn21){ref-type="table-fn"}
  Radiotherapy vs chemotherapy                                            1.07 (0.91 to 1.27)                                      1.00

Statistically significant *P* values after multiple test adjustment for pairwise treatment comparisons by Bonferroni corrections and hazard ratios (refer to Methods) are denoted by an asterisk. Variables associated with statistically significantly increased risk are denoted by an asterisk. In addition, by univariate Gray's test (not shown in [Table 6](#pkaa017-T6){ref-type="table"}), age (*P* \< .0001), race (*P* = .041), seminoma histology (*P* \< .001), and treatment (univariate comparison across 3 groups, *P* \< .001) statistically significantly affected risk of second primary solid cancers but not calendar year of TC diagnosis (*P* = .18) or stage of TC (*P* = .29). Clinical variables with univariate *P* ≤ .15 were included in the Fine and Gray model shown in this table (refer to Methods). CI = confidence interval; HR = hazard ratio; TCS = testicular cancer survivors.

Discussion
==========

In the largest population-based study of US TCS to date, we identified statistically significant 6% excesses of all solid-SMN taken together and almost 2-fold increased risks of leukemias. With more than 8000 survivors followed for over 20 years and more than 1600 solid-SMN, we described long-term patterns of risk. After radiotherapy, the 30-year cumulative incidence of solid-SMN among all TCS was almost 20% and after chemotherapy was approximately 10%. Statistically significantly elevated leukemia risks persisted for up to 10 years among all TCS and then decreased to expectation. These and other new findings are discussed below.

No US-based investigation ([@pkaa017-B9]) to date, to our knowledge, has comprehensively examined solid-SMN risk in TCS according to both initial management and histological type focusing on recent decades ([Table 5](#pkaa017-T5){ref-type="table"}). Two European studies ([@pkaa017-B5],[@pkaa017-B23]) examined solid-SMN risks without analyses by treatment type, whereas another European investigation ([@pkaa017-B6]) focused only on patients with stage I seminoma given radiotherapy ([Table 6](#pkaa017-T6){ref-type="table"}). The international investigation of TCS by Travis et al. ([@pkaa017-B17]) included population-based registries in Europe (two-thirds of patients) with TC diagnosed as early as 1943. Our estimates are based on considerably larger numbers of solid-SMN (n = 1625) than those in recent European cohorts (range n = 256--427) ([@pkaa017-B5],[@pkaa017-B23]). The lower overall risks of solid-SMN reported in the current study compared with recent European series ([@pkaa017-B5],[@pkaa017-B23]) ([Table 6](#pkaa017-T6){ref-type="table"}) are partially attributable to the population-based nature of our cohort. In contrast, several European series were hospital based ([@pkaa017-B6],[@pkaa017-B8]), leading to potential selection biases; another included contralateral TC in SMN risk estimates ([@pkaa017-B23]). Lower SMN risks in our survey may also reflect considerable changes in TC treatments in recent decades. These include the use of adjuvant chemotherapy \[ie, 1--2 cycles of bleomycin, etoposide, and cisplatin for stage I nonseminoma ([@pkaa017-B24],[@pkaa017-B25]) and single-dose carboplatin for stage I seminoma\] ([@pkaa017-B26]), which reduces the need for salvage therapy (typically 3--4 cycles of platinum-based chemotherapy or radiotherapy) ([@pkaa017-B27]). Increased adoption of active surveillance ([@pkaa017-B28],[@pkaa017-B29]) for stage I TC might also result in reduced overall risks of SMN; however, approximately 13% and 19% of stage I seminomas and nonseminomas, respectively, relapse within a few years ([@pkaa017-B30]); thus, subsequent salvage therapies might result in increased SMN risks after initial surgery alone for TC compared with the general population.

###### 

Overview of US studies providing risk estimates for incidence of second primary leukemias or solid cancers in TCS[\*](#tblfn22){ref-type="table-fn"}

                                                                              First author (citation) (year)                                                                                                                                                                                                           
  -------------------------------------------------------------------------- -------------------------------- -------------- -------------- -------------------------- ------------------------------------------------------- --------------------------------------------------------- -------------- -------------- --------------
  Patients, no.                                                                            5994                   12 691         16 463               24 900                                                                                                                                                           
  Calendar years of TC diagnosis                                                        1973--2000              1980--2008     1988--2013           1973--2014                                                                                                                                                         
  TC histology                                                                           Seminoma              Nonseminoma    Nonseminoma    Seminoma and nonseminoma                                                                                                                                                  
  Treatment group                                                                           RT                    No RT          Chemo.            Surgery only                                  RT                                                      No RT                            Surgery only   RT; no chemo   Chemo; no RT
  No. patients                                                                             4757                    1237           6013                 6678                                     9126                                                     7337                                 8995           9058           6340
  Median or mean follow-up, y (range)                                            15.1 \[mean\] (0--34.9)        12.3 (N/A)     7.3 (N/A)       7.4 (IQR: 3.3--12.1)                 8.3 \[mean\](IQR: 3.3--12.1)                14.7 for seminoma \[mean\]15.4 for nonseminoma \[mean\]                                
  Second leukemias, no.                                                                     13                      2             N/A                  N/A                                       N/A                                                      N/A                                  29             39             23
   SIR, overall                                                                            1.26                    0.85           N/A                  N/A                                       N/A                                                      N/A                                 1.76           1.39           2.68
   95% CI                                                                              0.67 to 2.16            0.10 to 3.09       N/A                  N/A                                       N/A                                                      N/A                             1.18 to 2.52   0.99 to 1.91   1.70 to 4.01
  Second solid cancers, no.                                                                347                      53            111                   99                                       N/A                                                      N/A                                 372            925            286
   SIR, overall                                                                            1.16                    0.77           1.43                 0.93                                      N/A                                                      N/A                                 0.83           1.13           1.26
   95% CI                                                                                  N/A                     N/A        1.18 to 1.73         0.76 to 1.14                                  N/A                                                      N/A                             0.75 to 0.92   1.06 to 1.21   1.12 to 1.41
  No. SMN[\*](#tblfn22){ref-type="table-fn"}                                               506                      89            N/A                  N/A                                       661                                                      298                                 N/A            N/A            N/A
   SIR or RR, overall                                                                   SIR: 1.51               SIR: 1.16         N/A                  N/A              Adjusted[^†^](#tblfn23){ref-type="table-fn"} RR: 1.84                             N/A                                 N/A            N/A       
   95% CI                                                                              1.38 to 1.64            0.93 to 1.43       N/A                  N/A                                  1.61 to 2.10                                                  N/A                                 N/A            N/A       
  Site-specific risks of solid cancers[^‡^](#tblfn24){ref-type="table-fn"}                 Yes                     Yes            Yes                  Yes                                       No                                                       Yes                                 Yes            Yes       

All SMN was defined by Lewinshtein et al. as "all malignancies," including cancers of testis, central nervous system, oral cavity, pharynx, thyroid, lung, hepatobiliary, pancreas, stomach, small bowel, colon, rectum, anus, kidney, upper urinary tract, urethra, bladder, prostate, and hematological malignancies including leukemia, lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma, and a category of "any hematological malignancy." In the study by Patel et al., the cancers comprising SMN were not specified. Chemo = chemotherapy; CI = confidence interval; IQR = interquartile range; PR = prevalence ratio; RR = risk ratio; RT = radiotherapy; SIR = standardized incidence ratio; SMN = second malignant neoplasm; TC = testicular cancer; TCS = testicular cancer survivors.

Mortality due to SMN was also reported: 82 deaths occurred after radiotherapy and 30 deaths occurred among patients not receiving radiotherapy, resulting in a prevalence ratio of 2.20 (95% CI not available).

Lewinshtein et al. also reported site-specific risks for hematological malignancies. All hematological malignancies after radiotherapy SIR = 1.44 (95% CI = 1.08 to 1.89), no radiotherapy SIR = 1.14 (95% CI = 0.52 to 2.17); all lymphomas after radiotherapy SIR = 1.67 (95% CI = 1.17 to 2.31), no radiotherapy SIR = 1.52 (95% CI = 0.61 to 3.13); non-Hodgkin lymphoma after radiotherapy SIR = 1.77 (95% CI = 1.22 to 2.48), no radiotherapy SIR = 1.50 (95% CI = 0.55 to 3.27); Hodgkin lymphoma after radiotherapy SIR = 1.03 (95% CI = 0.21 to 3.00), no radiotherapy SIR = 1.61 (95% CI = 0.04 to 8.95).

###### 

Overview of major European studies providing risk estimates for incidence of second primary leukemias or solid cancers in TCS[\*](#tblfn25){ref-type="table-fn"}

                                                                First author (citation) (year)                                                                                                                                                                                                                                                                                                            
  -------------------------------------------------------- ----------------------------------------- ----------------------- ------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ------------- ------------ ------------ -------------- ----------------------------- --------------
  Patients, no.                                                              9288                             5533                                       2629                                                         5190                                                         5848                                                                                                                   
  Calendar years of TC diagnosis                                          1960--2004                       1980--2006                                 1960--1992                                                   1984--2007                                                   1976--2007                                                                                                                
  Country or countries                                                      England                          Sweden                             United Kingdom, Norway                                               Denmark                                                    Netherlands                                                                                                               
  Cohort description                                           Pop.-based: London, S.E. England            Nationwide         Hospital-based[^‡^](#tblfn27){ref-type="table-fn"} (N = 12)                          Nationwide                           Hospital-based (N = 13)[^†^](#tblfn26){ref-type="table-fn"}                                                                                       
  TC histology                                                       Seminoma, nonseminoma            Seminoma, nonseminoma                       Seminoma (Stage 1)                        Seminoma, nonseminoma[^§^](#tblfn28){ref-type="table-fn"}                      Seminoma, nonseminoma                                                                                                          
  Treatment group                                                             N/A                              N/A                                        RT                                                      Surgery Only                                                      BEP                                   RT           MTOL        Total      Surgery Only   RT (with or without Chemo.)   Chemo. Only
  No. patients                                                               9288                             5533                                       2629                                                         3335                                                         1862                                   787          304          5848          2230                  1416                   2202
  Median follow-up, y (range)                                                 N/A                              N/A                              21.8 (IQR: 17.5--27.5)                                        14.4 (IQR: 8.6--20.5)                                        14.1 (IQR: 9.3--20.1)                                                                                                          
  Second leukemias, no.                                                       26                               18                                          9                                                           N/A                                                          N/A                                   N/A          N/A          N/A           N/A                    N/A                   N/A
  SIR, overall                                                              N/A^e^                            3.91                                       1.76                                                       HR = 0.8                                                     HR = 6.3                              HR = 2.6        N/A          N/A           N/A                    N/A                   N/A
  95% CI                                                                      N/A                         2.32 to 6.18                               0.92 to 3.38                                                  0.1 to 6.0                                                   2.2 to 18.2                           0.3 to 18.9      N/A          N/A           N/A                    N/A                   N/A
  Second solid cancers, no.                                                   383                              256                                        427                                                          N/A                                                          N/A                                   N/A          N/A          350            47                    185                   118
  SIR, overall                                                                N/A                              N/A                                        N/A                                                          N/A                                                          N/A                                   N/A          N/A          1.8           1.03                  1.91                   2.25
  95% CI                                                                      N/A                              N/A                                        N/A                                                          N/A                                                          N/A                                   N/A          N/A       1.6 to 2.0   0.75 to 1.36          1.64 to 2.20           1.86 to 2.70
  No. SMN[^¶^](#tblfn30){ref-type="table-fn"}                                 409                              274                                        436                                                          152                                                          104                                   78            27          N/A           N/A                    N/A                   N/A
  SIR or HR, overall[^‖^](#tblfn29){ref-type="table-fn"}    N/A[^‖^](#tblfn29){ref-type="table-fn"}        SIR = 1.99                                 SIR = 1.53                                                    HR = 1.0                                                     HR = 1.7                              HR = 1.8      HR = 3.7       N/A           N/A                    N/A                   N/A
  95% CI                                                                      N/A                         1.76 to 2.24                               1.39 to 1.68                                                  0.9 to 1.2                                                   1.4 to 2.0                            1.5 to 2.3    2.5 to 5.5      N/A           N/A                    N/A                   N/A
  Site-specific risks of solid cancers                                        Yes                              Yes                                        Yes                                                          Yes                                                          Yes                                   Yes          Yes          Yes           Yes                    Yes                   Yes

Table is restricted to investigations including only European patients and published in the last 15 years. BEP = bleomycin, etoposide, cisplatin; chemo = chemotherapy; CI = confidence interval; HR = hazard ratio; IQR = interquartile range; MTOL = more than one line of treatment; NPop. = population; RT = radiotherapy; SIR = standardized incidence ratio; SMN = second malignant neoplasm; TC = testicular cancer; TCS = testicular cancer survivors.

All study patients were treated at one of 13 Dutch hospitals.

Included 11 radiotherapy centers in the UK and one radiotherapy center in Norway.

Included gonadal and extragonadal tumors.

No overall results were presented. All results were shown only in terms of specific follow-up periods.

All SMN was defined as follows. Robinson et al.: all cancers excluding nonmelanoma skin cancer; Hemminki et al.: all cancers excluding TC; Horwich et al.: all cancers excluding nonmelanoma skin cancer and TC; Kier et al.: all cancers excluding nonmelanoma skin cancer and TC.

Within the radiotherapy-alone group, the increase in SIR for solid-SMN with more advanced TC ([Table 2](#pkaa017-T2){ref-type="table"}) likely represents underreporting of chemotherapy use and/or greater radiation exposure (with respect to dose and treatment field) with more advanced TC stage. Reductions in both radiotherapy fields (ipsilateral para-aortic lymphatics vs ipsilateral iliac and para-aortic lymphatics) ([@pkaa017-B14]) and doses (20 vs 30 Gy) ([@pkaa017-B31]) were adopted in Europe after randomized trials in stage I testicular seminoma reported that these modifications resulted in no statistically significant difference in relapse rates. In contrast, a 20- vs 30-Gy radiotherapy dose was not as widely adopted in the United States until more recently. Glaser et al. reported that the use of lower radiotherapy doses for stage I seminoma increased from 1.5%, 10%, and then 34% in 1999, 2010, and 2012, respectively ([@pkaa017-B32]). Commensurately, we reported that the 15-year cumulative incidence of solid-SMN following radiotherapy did not differ among TCS diagnosed in 1973--1999 vs 2000--2014. Given the typical more than 5- to 10-year latency periods for radiation-induced cancer ([@pkaa017-B33]), any reduction in risk as a result of a decrease in radiotherapy doses and fields may not manifest until much later. Thus, it will be important to determine whether decreases in radiotherapy dose exposure first recommended in the 1990--2000s ([@pkaa017-B14],[@pkaa017-B31]) will eventually result in reduced risks of SMN.

After radiotherapy, pancreatic cancer contributed to the largest AER of solid-SMN, followed by malignancies of the bladder, thyroid, rectum or recto-sigmoid, stomach, and soft tissue. A prior analytic study ([@pkaa017-B34]) reported statistically significant 2.9-fold increased risks of pancreatic cancers after TC radiotherapy, with risks associated with higher radiation doses (*P*~trend~ \< .001), and remaining elevated for 20  and more years after exposure (*P* \< .01). In our series, statistically significantly increased 5-fold risks of pancreatic cancer were apparent for over 30 years after radiotherapy for seminoma.

The urinary bladder ([@pkaa017-B33]) is susceptible to carcinogenic effects of radiotherapy. Travis et al. ([@pkaa017-B17]) reported statistically significant 2.7-fold increased risks of bladder cancer after radiotherapy alone for TC, similar to twofold increased risks 30+ years after seminoma radiotherapy reported here. The thyroid receives negligible radiation exposure during TC treatment (aside from the relatively few patients treated with supraclavicular nodal radiotherapy) ([@pkaa017-B35]). Accordingly, statistically significant thyroid cancer excesses 1--10 years after nonseminoma TC diagnosis were not consistent with radiation carcinogenesis and may have resulted from more frequent screening in TCS compared with the general population.

Similar to our investigation, two recent studies ([@pkaa017-B36],[@pkaa017-B37]) reported statistically significantly increased risks of colorectal and stomach cancers after radiotherapy. The Childhood Cancer Survivor Study ([@pkaa017-B37]) found a statistically significant 8.5-fold increased risk of colorectal cancer after abdominal radiotherapy, albeit based on 12 cases. An analytic study of 5-year TCS ([@pkaa017-B36]) reported a statistically significantly increased 5.9-fold risk of stomach cancer, with over 20-fold risks (*P*~trend~ \< .001) associated with gastric doses of at least 50 Gy  vs less than 10 Gy.

Statistically significant excesses of soft tissue cancers after radiotherapy for seminoma likely reflect known treatment effects ([@pkaa017-B33]). In contrast, early-onset sarcomas following chemotherapy for nonseminomatous TC may partially represent somatic-type malignancies arising from teratoma ([@pkaa017-B38],[@pkaa017-B39]), whereas those with a longer latency may reflect late effects of alkylating agents ([@pkaa017-B40]) or radiotherapy ([@pkaa017-B33]).

Within the chemotherapy-only group, a statistically significant SIR was observed only among those with metastatic disease ([Table 2](#pkaa017-T2){ref-type="table"}), suggestive of greater chemotherapy dose intensification within that subgroup. Platinum-based chemotherapy comprises the backbone of metastatic TC therapy ([@pkaa017-B27]), but cisplatin binds to and damages DNA, producing partly reactive platinum in the serum and platinum--DNA adducts in organs, detectable up to 20 years later ([@pkaa017-B41]). We found statistically significantly elevated 1.7- to 4.0-fold risks for SMN of pancreas, soft tissue, kidney, and thyroid following TC chemotherapy, with thyroid cancer contributing the largest AER, followed by kidney, pancreas, and soft tissue cancers. Wilson et al. ([@pkaa017-B42]) reported a 3.5-fold increased risk of renal carcinoma after cisplatin exposure in childhood cancer survivors, albeit based on four cases. Cisplatin is renally excreted, with urine platinum levels detectable for decades after cisplatin administration ([@pkaa017-B43]). Thus, acute and ongoing exposure of genitourinary epithelium to cisplatin may contribute to increased risks.

Prior reports showed that radiotherapy ([@pkaa017-B44],[@pkaa017-B45]) and cytotoxic drugs ([@pkaa017-B46]), including etoposide ([@pkaa017-B47]) and cisplatin ([@pkaa017-B44]), are associated with excess secondary leukemias in TCS, albeit based on few (n = 3--36) cases. Among more than 18 000 TCS followed-up for a mean of 10.2 years, Travis et al. ([@pkaa017-B44]) identified 36 cases of leukemia, 22 after radiotherapy alone. Median time to leukemia diagnosis was 5.0 years, with 25% occurring after one decade. Compared with a surgery-only referent group, increased risks of leukemia after radiotherapy alone and alkylating agents alone were 3- and 5-fold, respectively ([@pkaa017-B44]).

Based on the largest number of leukemias identified to date among TCS (n = 92), we found an overall statistically significantly increased 1.7-fold risk. AML comprised 44 cases, with an overall statistically significantly increased sevenfold risk after chemotherapy (n = 17), with statistically significant 13.7-fold and 5.2-fold risks 1--10 years and \>10--20 years after TC diagnosis, respectively (data not shown). Consistent with a prior report ([@pkaa017-B48]), CLL was not associated with elevated SIRs overall, or for any treatment group; similarly, elevated SIRs were not observed for CML.

The statistically significant 1.8-fold increased risks of leukemia we observed in the surgery-alone group and confined to the first few years after TC diagnosis likely reflect underreporting of subsequent therapies to SEER registries (discussed below) ([@pkaa017-B15],[@pkaa017-B16]).

Strengths of our study include the large number of TCS (n = 24 900) and SMN (n = 1853) derived from population-based registries, histological confirmation of all SMN, and long-term follow-up. Limitations inherent to the SEER Program include lack of data regarding types or doses of initial chemotherapy, doses and fields of radiotherapy, and information on subsequent courses of treatments. In our series, 85% TCS in the surgery-alone group had localized TC (data not shown). Some of these TCS subsequently received chemotherapy or radiotherapy (not reported to the SEER program) for relapse ([@pkaa017-B30]), which likely contributed to risks of SMN. SEER also does not collect data on other factors that may contribute to cancer excesses (eg, tobacco use, alcohol use, diet, physical activity levels, or comorbid conditions) or the type or frequency of radiologic imaging ([@pkaa017-B49]). Our results may also underestimate risks due to underreporting of SMN to SEER program registries when patients emigrate from SEER geographic areas in which TC was diagnosed ([@pkaa017-B16]). Such underascertainment may partially account for the lower SIRs observed here vs in European studies, which used nationwide registries ([@pkaa017-B5]).

Given our results demonstrating statistically significant excesses of solid-SMN and heme-SMN among large numbers of TCS in a population-based setting, efforts to minimize chemotherapy and radiotherapy exposures should continue. Future studies should quantify SMN risks during long-term (\>30--40 year) follow-up of TCS and determine the impact of decreases in treatment intensity, including reductions in radiotherapy dose and field size ([@pkaa017-B14],[@pkaa017-B31]). Ideally, survivorship care strategies should include counseling TCS with regard to age-appropriate cancer prevention, screening practices applicable to the general population ([@pkaa017-B41],[@pkaa017-B50]), smoking cessation, weight control, physical activity, and other factors consonant with adoption of a healthy lifestyle. A better understanding of tumor, genetic, and environmental factors affecting SMN risks could also help personalize treatment and follow-up recommendations ([@pkaa017-B51],[@pkaa017-B52]).
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